Stock data

台康生技 (6589)

台康生技 is a TWSE-listed company in Biotech & Medical Care. Revenue for September 2026 was NT$117.34M, up 43.2% from a year earlier. EPS over the last four quarters totals -NT$1.89.

Charts, drawing tools, and the P/E calculator are in the app, free to use.

Open 台康生技 in Insightr